Stay updated on Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial

Sign up to get notified when there's something new on the Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the dose escalation segment of a Phase 1b clinical trial involving XMT-1522 in patients with advanced breast cancer and other advanced tumors expressing HER2.
    Difference
    0.1%
    Check dated 2024-06-06T14:36:32.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, such as general health conditions and prior treatments, along with specific inclusion and exclusion criteria for the study. Previously, this section only indicated that no information was provided.
    Difference
    23%
    Check dated 2024-05-22T21:33:15.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:27:56.000Z thumbnail image

Stay in the know with updates to Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial page.